August 29, 2018
Over the next five years, the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, will award approximately $20 million to four academic centers to launch a new national Career Development Consortium for Excellence in Glycosciences.
June 6, 2016
…drug resistance in vivo, but also revealed a new therapeutic target.
June 13, 2019
…receives big investment for RNA therapeutics Local biotech company Locana made news last month when it raised $55 million in venture capital funding. Locana means “illuminate” or “vision” in Sanskrit, and the company is based on technology that was originally developed to illuminate RNA inside cells. While most gene therapy…
March 20, 2017
Genetic mutations that cause cancer also weaken cancer cells, allowing researchers to develop drugs that will selectively kill them. This is called “synthetic lethality” because the drug is only lethal to mutated (synthetic) cells. Researchers at UC San Diego School of Medicine and Jacobs School of Engineering developed a method…
November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of University of California…
January 9, 2012
The new UC San Diego-Roche Extending Innovation Network (EIN) program has been launched with selection of its first three research projects at the University of California, San Diego School of Medicine.
October 6, 2021
In a special issue of Nature, UC San Diego researchers further refine the organization of cells within key regions of the mouse brain and the organization of transcriptomic, epigenomic and regulatory factors that provide these brain cells with function and purpose.
August 28, 2024
…a novel mechanism of cardiac inflammation that may expand therapeutic opportunities to prevent heart attacks from becoming heart failure.
October 29, 2018
Biologists at UC San Diego have discovered a new way of re-sensitizing drug-resistant human tumor cells to the potency of DNA-damaging agents, the most widely used group of cancer drugs. In a new study, they describe how a human gene known as Schlafen 11 controls the sensitivity of tumor cells…
October 27, 2021
A new $9 million grant from Aligning Science Across Parkinson’s (ASAP) will enable advancement of UC San Diego’s discovery that inhibiting a single gene in mice converts other cell types directly into new neurons, alleviating all Parkinson’s symptoms.
